Stock News Releases and Press Releases OTCMKTS, NASDAQ and NYSE Markets

The Hague, July 1, 2024 - Aegon today announces the completion of its EUR 1.535 billion share buyback. As announced on July 6, 2023, EUR 1.5 billion of the share buyback relates to the transaction to combine Aegon the Netherlands with a.s.r. On April 9, 2024, Aegon announced that this sha...

Purchase of own shares LONDON, UNITED KINGDOM / ACCESSWIRE / July 1, 2024 / The Company announces that on 28 June 2024 it purchased the following number of its ordinary shares of 20 340/399 pence each through Goldman Sachs International (" GSI ") on the London Stock Exchange in accordance ...

CRH plc (NYSE: CRH), the leading provider of building materials solutions, is pleased to confirm that the previously announced Scheme of Arrangement (the “Scheme”) under which CRH and Barro Group (“Barro”) proposed to acquire Adbri Ltd. (“Adbri”) is now c...

Extension of Galaxy Loan LONDON, UNITED KINGDOM / ACCESSWIRE / July 1, 2024 / Argo Blockchain plc, (LSE:ARB)(NASDAQ:ARBK), a global leader in cryptocurrency mining using predominantly renewable energy, announces the extension of its loan with Galaxy Digital Holdings Ltd. ("Galaxy") through ...

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the develop...

Accenture (NYSE: ACN) has completed the acquisition of OPENSTREAM HOLDINGS and its subsidiaries, Open Stream and Neutral , to help clients reinvent their businesses with advanced digital technologies and become truly data-driven. Terms of the acquisition were not disclosed. This p...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ Nantes, France – July 1 st , 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR...